TIANFUCHEM--118288-08-7---Lafutidine CAS NO.118288-08-7

product name:lafutidinesynonyms:n-(4-(4-piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide;lafutidine;(+-)-2-(furfurylsulfinyl)-n-(4-(4-(piperidinomethyl)-2-pyridyl)oxy-(z)-2-but;(z)-inyl)oxy)-2-butenyl);acetamide,2-((2-furanylmethyl)sulfinyl)-n-(4-((4-(1-piperidinylmethyl)-2-pyrid;enyl)acetamide;frg-8813;lafutidine(subjecttopatentfree)cas:118288-08-7mf:c22h29n3o4smw:431.55einecs:product categories:active pharmaceutical ingredients;heterocycles;intermediates & fine chemicals;pharmaceuticals;sulfur & selenium compounds;other apismol file:118288-08-7.mol

lafutidine chemical properties
melting point 92.7-94.9°cas database reference118288-08-7(cas database reference)
safety information
safety statements 24/25
msds information
lafutidine usage and synthesis
descriptionlafutidine is a second generation of h2-receptor antagonist. h2-receptor antagonist can strongly inhibit gastric acid secretion compared with conventional drugs such as antacids. unlike conventional h2-receptor antagonist, lafutidine inhibits gastric acid secretion during daytime as well as nighttime in clinical studies in humans. lafutidine also has gastroprotective activity independent of its acid antisecretory efficacy, preventing noxious agent-induced gastric mucosal injury and accelerating the repair process following gastric mucosal damage. it also protects experimentally induced reflux esophagitis, indomethacin-induced intestinal, and dextran sulfate sodium-induced colonic inflammation.
lafutidine is used for gastric and duodenal ulcers. it is also confirmed that lafutidine can be used as an empiric treatment and superior efficacy for primary care practice patients with dyspepsia.references[1] tomohiko shimatani, masaki inoue, tomoko kuroiwa, jing xu, masuo nakamura, susumu tazuma, kazuro ikawa, norifumi morikawa (2006) lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric ph and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine, digestive diseases and sciences, 51, 114-120
[2] bhupesh dewan, nisha philipose (2011) lafutidine 10 mg versus rabeprazole 20 mg in the treatment of patients with heartburn-dominant uninvestigated dyspepsia: a randomized, multicentric trial, gastroenterology research and practice, 2011, article id 640685
[3] # generation histamine h2-receptor antagonist. antiulcerativeuseslafutidine, a newly developed histamine h(2)-receptor antagonist, inhibits gastric acid secretion